Dr. Vanessa Sepúlveda-Rivera

IGC Pharma, Inc. (IGC), a leading cannabinoid-based formulation developer, has expanded its Phase 2 clinical trial for IGC-AD1, a natural THC-based investigational drug for Alzheimer's disease, to the University of Puerto Rico network. IGC is dedicated to developing advanced cannabinoid-based...